Takeda and Bristol Myers Squibb were among the investors that helped the cellular medicine developer close its series B round.
US-based cellular medicine developer Be Biopharma has completed a $130m series B round featuring pharmaceutical companies Bristol Myers Squibb and Takeda.
Arch Venture Partners led the round with backing from Atlas Venture, RA Capital Management, Longwood Fund and Alta Partners, while Takeda participated through corporate venturing unit Takeda Ventures.
Founded in 2020 by Longwood Fund, Be Bio is developing therapies by engineering B cells, a type of white blood cell that produces proteins and antibodies.
The startup’s product pipeline is…
Fernando Moncada Rivera
Fernando Moncada Rivera is a reporter at Global Corporate Venturing and also host of the CVC Unplugged podcast.
